Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome
Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease. As of writing this article, there are over 4.4 million people affected by COVID-19, and unfortunately, 300,000 have succumbed to the infection. In this article, we address a particularly more susceptib...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2020/8829309 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560023786487808 |
|---|---|
| author | Sudeendra Gupta Rakesh Madhyastha Fadi Hamed Maher Balkis Wasim El Nekidy Nizar Attallah |
| author_facet | Sudeendra Gupta Rakesh Madhyastha Fadi Hamed Maher Balkis Wasim El Nekidy Nizar Attallah |
| author_sort | Sudeendra Gupta |
| collection | DOAJ |
| description | Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease. As of writing this article, there are over 4.4 million people affected by COVID-19, and unfortunately, 300,000 have succumbed to the infection. In this article, we address a particularly more susceptible group of the population of end-stage renal disease (ESRD) patients on dialysis who may potentially benefit from being treated with tocilizumab. The use of tocilizumab has not been reported widely in ESRD patients on dialysis to treat COVID-19. In this case report, we describe a patient with ESRD on hemodialysis who was admitted to the intensive care unit, with severe pneumonia secondary to COVID-19 infection. This patient was treated with tocilizumab 400 mg intravenous and had a favorable outcome with no apparent adverse events. |
| format | Article |
| id | doaj-art-2d078393bf5b475c8fe5e09efa2e282b |
| institution | Kabale University |
| issn | 2090-6641 2090-665X |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Nephrology |
| spelling | doaj-art-2d078393bf5b475c8fe5e09efa2e282b2025-02-03T01:28:30ZengWileyCase Reports in Nephrology2090-66412090-665X2020-01-01202010.1155/2020/88293098829309Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress SyndromeSudeendra Gupta0Rakesh Madhyastha1Fadi Hamed2Maher Balkis3Wasim El Nekidy4Nizar Attallah5Medical Sub-specialities Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAEMedical Sub-specialities Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAECritical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAEMedical Sub-specialities Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAEDepartment of Pharmacy, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAEMedical Sub-specialities Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAENovel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease. As of writing this article, there are over 4.4 million people affected by COVID-19, and unfortunately, 300,000 have succumbed to the infection. In this article, we address a particularly more susceptible group of the population of end-stage renal disease (ESRD) patients on dialysis who may potentially benefit from being treated with tocilizumab. The use of tocilizumab has not been reported widely in ESRD patients on dialysis to treat COVID-19. In this case report, we describe a patient with ESRD on hemodialysis who was admitted to the intensive care unit, with severe pneumonia secondary to COVID-19 infection. This patient was treated with tocilizumab 400 mg intravenous and had a favorable outcome with no apparent adverse events.http://dx.doi.org/10.1155/2020/8829309 |
| spellingShingle | Sudeendra Gupta Rakesh Madhyastha Fadi Hamed Maher Balkis Wasim El Nekidy Nizar Attallah Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome Case Reports in Nephrology |
| title | Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome |
| title_full | Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome |
| title_fullStr | Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome |
| title_full_unstemmed | Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome |
| title_short | Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome |
| title_sort | tocilizumab use in a chronic hemodialysis patient for the management of covid 19 associated pneumonia and acute respiratory distress syndrome |
| url | http://dx.doi.org/10.1155/2020/8829309 |
| work_keys_str_mv | AT sudeendragupta tocilizumabuseinachronichemodialysispatientforthemanagementofcovid19associatedpneumoniaandacuterespiratorydistresssyndrome AT rakeshmadhyastha tocilizumabuseinachronichemodialysispatientforthemanagementofcovid19associatedpneumoniaandacuterespiratorydistresssyndrome AT fadihamed tocilizumabuseinachronichemodialysispatientforthemanagementofcovid19associatedpneumoniaandacuterespiratorydistresssyndrome AT maherbalkis tocilizumabuseinachronichemodialysispatientforthemanagementofcovid19associatedpneumoniaandacuterespiratorydistresssyndrome AT wasimelnekidy tocilizumabuseinachronichemodialysispatientforthemanagementofcovid19associatedpneumoniaandacuterespiratorydistresssyndrome AT nizarattallah tocilizumabuseinachronichemodialysispatientforthemanagementofcovid19associatedpneumoniaandacuterespiratorydistresssyndrome |